Karyotypic Findings in Chronic Myeloid Leukemia Cases Undergoing Treatment

Overview

Journal Indian J Hum Genet

Specialty Genetics

Date 2012 Jul 4

PMID 22754224

Authors

Anupam Kaur

Simran Preet Kaur

Amarjit Singh

Jai Rup Singh

Affiliations

Soon will be listed here.

Abstract

Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative expansion of primitive hematopoietic progenitor cells.

Materials And Methods: In the present study, CML samples were collected from various hospitals in Amritsar, Jalandhar and Ludhiana.

Results: Chromosomal alterations seen in peripheral blood lymphocytes of these treated and untreated cases of CML were satellite associations, double minutes, random loss, gain of C group chromosomes and presence of marker chromosome. No aberrations were observed in control samples. Karyotypic abnormalities have also been noted in the Ph-negative cells of some patients in disease remission.

Conclusion: This is a novel phenomenon whose prognostic implications require thorough and systematic evaluation.

References

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

Rowley J . Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243(5405):290-3. DOI: 10.1038/243290a0. View

Ames B . Micronutrient deficiencies. A major cause of DNA damage. Ann N Y Acad Sci. 2000; 889:87-106. DOI: 10.1111/j.1749-6632.1999.tb08727.x. View

Bumm T, Muller C, Al-Ali H, Krohn K, Shepherd P, Schmidt E . Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2002; 101(5):1941-9. DOI: 10.1182/blood-2002-07-2053. View

Herens C, Brasseur E, Jamar M, Vierset L, Schoenen I, Koulischer L . Loss of the Y chromosome in bone marrow cells: results on 1907 consecutive cases of leukaemia and preleukaemia. Clin Lab Haematol. 1999; 21(1):17-20. DOI: 10.1046/j.1365-2257.1999.00173.x. View

Kantarjian H, Keating M, Walters R, McCredie K, Smith T, Talpaz M . Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer. 1986; 58(9):2023-30. DOI: 10.1002/1097-0142(19861101)58:9<2023::aid-cncr2820580912>3.0.co;2-h. View

Karrman K, Sallerfors B, Lenhoff S, Fioretos T, Johansson B . Cytogenetic evolution patterns in CML post-SCT. Bone Marrow Transplant. 2007; 39(3):165-71. DOI: 10.1038/sj.bmt.1705560. View

MEINERT R, Schuz J, Kaletsch U, Kaatsch P, Michaelis J . Leukemia and non-Hodgkin's lymphoma in childhood and exposure to pesticides: results of a register-based case-control study in Germany. Am J Epidemiol. 2001; 151(7):639-46; discussion 647-50. DOI: 10.1093/oxfordjournals.aje.a010256. View

Sawyers C . Chronic myeloid leukemia. N Engl J Med. 1999; 340(17):1330-40. DOI: 10.1056/NEJM199904293401706. View

10.

Kantarjian H, Shan J, Jones D, OBrien S, Rios M, Jabbour E . Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009; 27(22):3659-63. PMC: 2799063. DOI: 10.1200/JCO.2008.18.6999. View

11.

Loriaux M, Deininger M . Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma. 2004; 45(11):2197-203. DOI: 10.1080/10428190410001723278. View

12.

Deininger M . Cytogenetic studies in patients on imatinib. Semin Hematol. 2003; 40(2 Suppl 2):50-5. DOI: 10.1053/shem.2003.50043. View

13.

Chavan D, Ahmad F, Iyer P, Dalvi R, Kulkarni A, Mandava S . Cytogenetic investigation in chronic myeloid leukemia: study from an Indian population. Asian Pac J Cancer Prev. 2006; 7(3):423-6. View

14.

McDonald T, Holland N, Skibola C, Duramad P, Smith M . Hypothesis: phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia. 2001; 15(1):10-20. DOI: 10.1038/sj.leu.2401981. View